{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:03:13Z","timestamp":1788397393626,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.transproceed.2020.01.163","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T07:34:39Z","timestamp":1592638479000},"page":"1852-1854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["One Year of Preemptive Valganciclovir Administration in Children After Liver Transplantation"],"prefix":"10.1016","volume":"52","author":[{"given":"Takehisa","family":"Ueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonari","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tazuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroomi","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2020.01.163_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.transproceed.2020.01.163_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0168-8278(00)80195-6","article-title":"Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients","volume":"32","author":"Smets","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2020.01.163_bib3","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2020.01.163_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/lt.22471","article-title":"Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir","volume":"18","author":"Bedel","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2020.01.163_bib5","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/ajt.12755","article-title":"Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers","volume":"14","author":"Danziger-Isakov","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/TP.0b013e31822d873d","article-title":"A\u00a0universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation","volume":"92","author":"Saitoh","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2020.01.163_bib8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib9","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/petr.12179","article-title":"New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients","volume":"18","author":"Asberg","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1399-3046.2010.01330.x","article-title":"The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation","volume":"14","author":"Lapidus-Krol","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2020.01.163_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/lt.21498","article-title":"Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus","volume":"14","author":"Hierro","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2020.01.163_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2008.02528.x","article-title":"Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients","volume":"9","author":"Vaudry","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519318512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519318512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:37:00Z","timestamp":1758577020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134519318512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0041134519318512"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2020.01.163","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One Year of Preemptive Valganciclovir Administration in Children After Liver Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2020.01.163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}